trending Market Intelligence /marketintelligence/en/news-insights/trending/vqbheqbtzb0b8szgjhslya2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Protagonist Therapeutics shares tank after decision to discontinue drug study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Protagonist Therapeutics shares tank after decision to discontinue drug study

Protagonist Therapeutics Inc. is terminating a study designed to establish the effectiveness of its drug PTG-100 to treat ulcerative colitis, an inflammatory bowel disease.

The Neward, Calif.-based biopharmaceutical company's stock price was down 41.75% to $11.90 per share in premarket trading March 26.

Protagonist Therapeutics' decision was prompted by the findings of the study's independent data monitoring committee that said the phase 2b trial — known as Propel — was "futile."

The committee based its conclusion on the efficacy and safety data from the first 65 patients of the 240 subjects enrolled in the trial to study the number of patients whose symptoms or active disease went away.

"We will conduct an extensive review of the complete dataset on the totality of patients enrolled in the trial before making any further decisions about the future development of PTG-100," Protagonist Therapeutics President and CEO Dinesh Patel said in a statement.

Protagonist Therapeutics will postpone the initiation of a phase 2/3 clinical trial of PTG-100 in patients with chronic pouchitis until a full review is conducted on the findings from the Propel study.